Loading
Angiex is developing an antibody-drug conjugate, an antibody that carries a chemotherapy drug, aimed at a protein called TM4SF1 on cancer cells and on the blood vessels that feed tumours. Its first medicine, AGX101, is in an early trial in advanced solid tumours.
Angiex Inc., a privately held company based in Cambridge, Massachusetts, develops what it calls Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs), designed to carry a chemotherapy payload into the nucleus of tumour cells and of tumour blood vessel endothelial cells. Its founders include Paul Jaminet, its chief executive, Shou-Ching Jaminet, a TM4SF1 researcher formerly at Beth Israel Deaconess Medical Center and Harvard Medical School, and Hal Dvorak. The lead ND-ADC AGX101 targets TM4SF1. In November 2025 the company announced the completion of financings totalling USD 31 million, including a USD 16 million equity offering placed by Paulson Investment Company, to take AGX101 through dose escalation. Its first registered cancer trial, NCT06440005, a phase 1 dose-escalation and expansion study of AGX101 in unresectable, locally advanced or metastatic solid tumours including breast, prostate, colorectal, pancreatic and liver cancers and angiosarcoma, was posted on ClinicalTrials.gov in June 2024.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Financing · Financings totalling USD 31 million from new and existing investors, including a USD 16 million equity offering | 2025 | $31M | angiex.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/